331254 RESULTS
RESEARCH MODELS Summary The PS1 P264L knock-in mouse line was derived using a two-step mutagenesis strategy similar to that used to generate the TgAPPSwe-KI line (Reaume et al., 1996). An advantage to this model is the mutant PSEN1 is expressed at normal levels and under
Sweden
RESEARCH MODELS Summary This model was generated using a gene-targeting strategy designed to enhance the production of human Aβ in the mouse brain without changing APP synthesis. Site-specific mutations were introduced into exon 16 of the mouse APP gene to humanize the A
RESEARCH MODELS Summary These mice were generated to determine how BACE overexpression affects the processing of APP in vivo. Two transgenic lines were reported (BACE54/4 and BACE54/11) both expressing human BACE at high levels in the brain. Human BACE mRNA was approxima
University of Rochester Medical CenterUnited States
RESEARCH MODELS Modification Details Human 4-repeat tau driven by the PDGF-β promoter. Tagged with myc and Flag on the N- and C-terminals respectively. Neuropathology SDS-insoluble tau aggregates in hippocampus. Degenerating neurons in the hippocampus containing phosphor
RESEARCH MODELS Modification Details Transgene containing human 4-repeat tau cDNA with the R406W mutation containing myc and FLAG tags at N-and C-terminal ends, respectively, and driven by the CaMK-II promoter. Neuropathology Argyrophilic and congophilic tau inclusions i
RESEARCH MODELS Summary Three lines of transgenic mice expressing different levels of human BACE were generated. Line 30 (BACE-L) expressed the lowest amount of BACE, followed by line 34 (BACE-M), and line 8 (BACE-H). These lines expressed human BACE at levels approximat
COMMENT We will miss his generosity in sharing information and antibodies, his stuborness and his willingness to discuss, his big mind in his big body... fred.vanleuven 0
COMMENT In response to Dr. Kennedy's comments: 1. Our structural model for Aβ40 fibrils from patient 1, described in this paper, was calculated with Xplor-NIH software using 197 NMR-based experimental structural restraints (4.925 restraints per residue on av
CONFERENCE COVERAGE 2013-11-27 Conference Coverage Slow enrollment often hobbles Alzheimer’s clinical trials. At a November 1–2 meeting at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, stakeholders brainstormed ways to reach new participants and keep them engaged.
CONFERENCE COVERAGE 2013-11-27 Conference Coverage Pathology studies show that tau tangles, unlike amyloid, track closely with the cognitive decline of Alzheimer’s disease. This has raised hope that the tau PET tracers being developed will allow researchers to stage disease, and early
PAPER Hoffman P, Evans GA, Lambon Ralph MA
PAPER Eisen A, Turner MR, Lemon R
PAPER Dulovic M, Jovanovic M, Xilouri M, Stefanis L, Harhaji-Trajkovic L, Kravic-Stevovic T, Paunovic V, Ardah MT, El-Agnaf OM, Kostic V, Markovic I, Trajkovic V
No filters selected
